LMAT on Nasdaq
LEMAITRE VASCULAR INC
In its 2026 annual report the company says: “We are a global provider of medical devices and human tissue cryopreservation services largely used in the treatment of peripheral vascular disease, end-stage renal disease, and cardiovascular disease. We develop, manufacture, and market vascular devices to address the needs of vascular surgeons and, to a lesser degree, other specialties such as cardiac surgeons, general surgeons, and neurosurgeons. Our diversified portfolio of devices consists of brand name products that are used in arteries and veins and are well known to vascular surgeons.”5 It is headquartered in Burlington, Massachusetts.1 Its shares trade on Nasdaq under the symbol LMAT.1
$83.86 up 1.24 (1.50%)Price as of Oct 15, 2026 at 17:33 UTC
Last updated Oct 21, 2026.
Overview
Compare with ORTHOPEDIATRICS CORP, CERUS CORP or TREACE MEDICAL CONCEPTS, INC., or pick any stock.
- TickerLMAT on Nasdaq1
- IndustrySurgical & Medical Instruments & Apparatus1
- HeadquartersBurlington, Massachusetts1
- Business address63 Second Avenue, Burlington, Ma 018033
- Filer categoryLarge accelerated filer3
See how the biggest companies compare on our leaderboards
We are a global provider of medical devices and human tissue cryopreservation services largely used in the treatment of peripheral vascular disease, end-stage renal disease, and cardiovascular disease. We develop, manufacture, and market vascular devices to address the needs of vascular surgeons and, to a lesser degree, other specialties such as cardiac surgeons, general surgeons, and neurosurgeons. Our diversified portfolio of devices consists of brand name products that are used in arteries and veins and are well known to vascular surgeons. Our principal product offerings are sold globally, primarily in the United States, Europe, Canada and Asia Pacific. We estimate that the annual worldwide market for peripheral vascular devices exceeds $9 billion, within which we estimate that the market for our products is approximately $1 billion.5 From its latest annual report
Financials
From the company’s reports to the SEC. Every number links to the filing it came from.
Key numbers, fiscal 2025
What sells
Revenue by product, business segment and region, as the company reports it to the SEC.
Regions
United States brought in 42% of the revenue LEMAITRE VASCULAR INC broke down this way in fiscal 2025.
Regions by year
| Regions | 2023 | 2024 | 2025 |
|---|---|---|---|
| United States | $117.8M | $128.7M | $141.6M |
| EMEA | $51.1M | $60.0M | $73.1M |
| Other Countries | $42.9M | $52.1M | $61.7M |
| Germany | $13.4M | $14.4M | $17.9M |
| Asia Pacific | $12.1M | $15.3M | $16.8M |
| Canada | $10.8M | $13.7M | $15.3M |
| United Kingdom | $8.6M | $11.0M | $13.2M |
Where the money goes
Where each dollar of revenue went, fiscal 2025
- Cost of revenue28¢$71.1M
- Research and development6¢$14.1M
- Other costs34¢$84.0M
- Interest2¢$5.2M
- Income tax7¢$17.4M
- Profit23¢$57.7M
Out of $249.6M in revenue.6
Where each dollar of operating cash went, fiscal 2025
- Dividends paid22¢$18.1M
- Share buybacks2¢$1.8M
- Kept or used elsewhere75¢$61.3M
Out of $81.3M of cash from operations.6
Financial statements
Every line of the income statement as filed: the last 4 fiscal years, latest first.6
| Period ending | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Net sales | $249.6M | $219.9M | $193.5M | |
| Cost of sales | $71.1M | $69.0M | $66.4M | |
| Gross profit | $178.5M | $150.9M | $127.0M | |
| Sales and marketing | $54.5M | $46.7M | $41.1M | |
| General and administrative | $42.0M | $36.3M | $31.8M | |
| Research and development | $14.1M | $15.7M | $17.0M | |
| Restructuring | $0 | $0 | $485.0K | $3.1M |
| Total operating expenses | $110.6M | $98.6M | $90.3M | |
| Income from operations | $67.9M | $52.3M | $36.7M | |
| Investment income | $13.1M | $4.9M | $3.1M | |
| Interest expense | -$5.2M | -$205.0K | ||
| Other income (loss), net | -$638.0K | -$125.0K | -$314.0K | |
| Income before income taxes | $75.2M | $56.9M | $39.5M | |
| Provision for income taxes | $17.4M | $12.8M | $9.4M | |
| Net income | $57.7M | $44.0M | $30.1M | |
| Basic (in dollars per share) | $2.55 | $1.96 | $1.36 | |
| Diluted (in dollars per share) | $2.52 | $1.93 | $1.34 | |
| Basic (in shares) | 22.6M shares | 22.5M shares | 22.2M shares | |
| Diluted (in shares) | 22.9M shares | 22.8M shares | 22.4M shares | |
| Cash dividends declared per common share (in dollars per share) | $0.80 | $0.64 | $0.56 |
No quarter-by-quarter statement was filed.
Every line of the balance sheet as filed: the last 4 fiscal years (annual) or 4 quarters (quarterly), latest first.6
| Period ending | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Cash and cash equivalents | $28.2M | $25.6M | ||
| Short-term marketable securities | $330.9M | $274.1M | ||
| Accounts receivable, net of allowances of $1,400 at December 31, 2025 and $1,369 at December 31, 2024 | $33.6M | $30.1M | ||
| Inventory and other deferred costs | $70.4M | $64.9M | ||
| Prepaid expenses and other current assets | $5.1M | $7.5M | ||
| Total current assets | $468.2M | $402.2M | ||
| Property and equipment, net | $27.0M | $24.8M | ||
| Right-of-use leased assets | $15.8M | $16.8M | ||
| Goodwill | $65.9M | $65.9M | ||
| Other intangibles, net | $33.1M | $35.8M | ||
| Deferred tax assets | $759.0K | $1.4M | ||
| Other assets | $4.9M | $4.9M | ||
| Total assets | $615.7M | $551.8M | ||
| Accounts payable | $3.6M | $1.8M | ||
| Accrued expenses | $29.4M | $24.7M | ||
| Acquisition-related obligations | $322.0K | $1.4M | ||
| Lease liabilities - short-term | $2.9M | $2.7M | ||
| Total current liabilities | $36.3M | $30.6M | ||
| Convertible senior notes, net | $168.6M | $167.8M | ||
| Lease liabilities - long-term | $14.0M | $15.2M | ||
| Deferred tax liabilities | $1.7M | $85.0K | ||
| Other long-term liabilities | $1.5M | $831.0K | ||
| Total liabilities | $222.2M | $214.5M | ||
| Common stock, $0.01 par value; 37,000,000 shares authorized, 24,396,904 and 24,153,165 shares issued, 22,772,607 and 22,549,340 shares outstanding, respectively | $244.0K | $242.0K | ||
| Additional paid-in capital | $228.4M | $213.8M | ||
| Retained earnings | $184.7M | $145.1M | ||
| Accumulated other comprehensive loss | -$2.4M | -$6.2M | ||
| Treasury stock, at cost; 1,624,297 and 1,603,825 shares, respectively | -$17.4M | -$15.6M | ||
| Total stockholders equity | $393.5M | $337.3M | $297.9M | $268.2M |
| Total liabilities and stockholders equity | $615.7M | $551.8M | ||
| Accounts Receivable, Allowance for Credit Loss, Current | $1.4M | $1.4M | ||
| Preferred stock, par value | $0.01 | $0.01 | ||
| Preferred Stock, Shares Authorized | 3.0M shares | 3.0M shares | ||
| Preferred stock, shares issued | 0 shares | 0 shares | ||
| Preferred stock, shares outstanding | 0 shares | 0 shares | ||
| Common stock, par value | $0.01 | $0.01 | ||
| Common Stock, Shares Authorized | 37.0M shares | 37.0M shares | ||
| Common Stock, Shares, Issued | 24.4M shares | 24.2M shares | ||
| Common stock, shares, outstanding | 22.8M shares | 22.5M shares | ||
| Treasury Stock, Common, Shares | 1.6M shares | 1.6M shares |
| Period ending | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Cash and cash equivalents | $28.2M | $25.6M | ||
| Short-term marketable securities | $330.9M | $274.1M | ||
| Accounts receivable, net of allowances of $1,400 at December 31, 2025 and $1,369 at December 31, 2024 | $33.6M | $30.1M | ||
| Inventory and other deferred costs | $70.4M | $64.9M | ||
| Prepaid expenses and other current assets | $5.1M | $7.5M | ||
| Total current assets | $468.2M | $402.2M | ||
| Property and equipment, net | $27.0M | $24.8M | ||
| Right-of-use leased assets | $15.8M | $16.8M | ||
| Goodwill | $65.9M | $65.9M | ||
| Other intangibles, net | $33.1M | $35.8M | ||
| Deferred tax assets | $759.0K | $1.4M | ||
| Other assets | $4.9M | $4.9M | ||
| Total assets | $615.7M | $551.8M | ||
| Accounts payable | $3.6M | $1.8M | ||
| Accrued expenses | $29.4M | $24.7M | ||
| Acquisition-related obligations | $322.0K | $1.4M | ||
| Lease liabilities - short-term | $2.9M | $2.7M | ||
| Total current liabilities | $36.3M | $30.6M | ||
| Convertible senior notes, net | $168.6M | $167.8M | ||
| Lease liabilities - long-term | $14.0M | $15.2M | ||
| Deferred tax liabilities | $1.7M | $85.0K | ||
| Other long-term liabilities | $1.5M | $831.0K | ||
| Total liabilities | $222.2M | $214.5M | ||
| Common stock, $0.01 par value; 37,000,000 shares authorized, 24,396,904 and 24,153,165 shares issued, 22,772,607 and 22,549,340 shares outstanding, respectively | $244.0K | $242.0K | ||
| Additional paid-in capital | $228.4M | $213.8M | ||
| Retained earnings | $184.7M | $145.1M | ||
| Accumulated other comprehensive loss | -$2.4M | -$6.2M | ||
| Treasury stock, at cost; 1,624,297 and 1,603,825 shares, respectively | -$17.4M | -$15.6M | ||
| Total stockholders equity | $393.5M | $337.3M | $297.9M | $268.2M |
| Total liabilities and stockholders equity | $615.7M | $551.8M | ||
| Accounts Receivable, Allowance for Credit Loss, Current | $1.4M | $1.4M | ||
| Preferred stock, par value | $0.01 | $0.01 | ||
| Preferred Stock, Shares Authorized | 3.0M shares | 3.0M shares | ||
| Preferred stock, shares issued | 0 shares | 0 shares | ||
| Preferred stock, shares outstanding | 0 shares | 0 shares | ||
| Common stock, par value | $0.01 | $0.01 | ||
| Common Stock, Shares Authorized | 37.0M shares | 37.0M shares | ||
| Common Stock, Shares, Issued | 24.4M shares | 24.2M shares | ||
| Common stock, shares, outstanding | 22.8M shares | 22.5M shares | ||
| Treasury Stock, Common, Shares | 1.6M shares | 1.6M shares |
Cash flow is reported year to date, not quarter by quarter, so there are no separate quarterly figures.
Every line of the cash flow as filed: the last 3 fiscal years, latest first.6
| Period ending | 2025-12-31 | 2024-12-31 | 2023-12-31 |
|---|---|---|---|
| Net income | $57.7M | $44.0M | $30.1M |
| Depreciation and amortization | $10.4M | $9.6M | $9.5M |
| Stock-based compensation | $7.8M | $6.6M | $5.3M |
| Amortization of issuance costs on convertible senior notes | $873.0K | $62.0K | $0 |
| Provision for inventory write-downs | $2.7M | $3.1M | $2.2M |
| Provision (benefit) for deferred income taxes | $2.3M | -$451.0K | $783.0K |
| Loss on divestitures | $0 | $0 | $485.0K |
| Provision for credit losses | $817.0K | $813.0K | $344.0K |
| Unrealized loss on equity investments | $535.0K | $0 | $0 |
| Fair value adjustments to contingent consideration obligations | $134.0K | -$78.0K | |
| Foreign currency transaction effect on income | -$176.0K | $362.0K | -$705.0K |
| Accounts receivable | -$2.9M | -$6.4M | -$3.1M |
| Inventory and other deferred costs | -$7.2M | -$10.6M | -$9.8M |
| Prepaid expenses and other assets | $2.4M | -$2.3M | -$2.9M |
| Accounts payable and other liabilities | $4.2M | -$923.0K | $4.6M |
| Accrued interest | $1.8M | $144.0K | $0 |
| Net cash provided by operating activities | $81.3M | $44.1M | $36.8M |
| Purchases of short-term marketable securities | -$641.3M | -$277.9M | -$16.6M |
| Purchases of property and equipment | -$6.8M | -$7.0M | -$7.3M |
| Payments related to acquisitions, net of cash acquired | -$1.9M | $0 | -$899.0K |
| Proceeds from sales of short-term marketable securities | $585.1M | $84.8M | $0 |
| Net cash used in investing activities | -$64.9M | -$200.1M | -$24.7M |
| Proceeds from issuance of convertible senior notes, net of issuance costs paid of $3,234 | $0 | $169.3M | $0 |
| Costs paid related to issuance of convertible senior notes | -$3.2M | ||
| Common stock cash dividend paid | -$18.1M | -$14.4M | -$12.4M |
| Proceeds from stock option exercises | $6.8M | $6.4M | $6.2M |
| Payment of withholding taxes in connection with net settlement of equity awards | -$1.8M | -$1.7M | -$853.0K |
| Deferred payments for acquisitions | -$1.4M | $0 | $0 |
| Net cash (used in) provided by financing activities | -$14.5M | $158.1M | -$7.1M |
| Effect of exchange rate changes on cash and cash equivalents | $864.0K | -$765.0K | $230.0K |
| Net increase in cash and cash equivalents | $2.6M | $1.3M | $5.1M |
No quarter-by-quarter statement was filed.
Corporate structure
LEMAITRE VASCULAR INC sits at the top of its group. 13 entities, 10 countries on record. Switch between the flow chart and the network, and select any entity to see its details.
Major holders of LEMAITRE VASCULAR INC
- FIRST TRUST PORTFOLIOS LP Filed SCHEDULE 13G on LEMAITRE VASCULAR INC, latest Jul 27, 2026
- George W. Lemaitre Filed SCHEDULE 13G/A on LEMAITRE VASCULAR INC, latest May 14, 2026 (6 filings since Feb 11, 2022)
- VANGUARD GROUP INC Filed SCHEDULE 13G/A on LEMAITRE VASCULAR INC, latest Mar 27, 2026 (4 filings since Feb 10, 2022)
- Conestoga Capital Advisors, LLC Filed SCHEDULE 13G/A on LEMAITRE VASCULAR INC, latest Jan 9, 2026 (5 filings since Jan 10, 2022)
- BlackRock Filed SCHEDULE 13G/A on LEMAITRE VASCULAR INC, latest Apr 29, 2025 (8 filings since Jan 28, 2022)
- Copeland Capital Management, LLC Filed SCHEDULE 13G on LEMAITRE VASCULAR INC, latest Jan 24, 2025 (5 filings since Jan 26, 2022)
- LEMAITRE VASCULAR INC Burlington, Massachusetts
- Bio Nova Holdings Pty Ltd Subsidiary · Australia
- Bio Nova International Pty Ltd Subsidiary · Australia
- LeMaitre Acquisition LLC Subsidiary · Delaware, United States
- LeMaitre Cardial SAS Subsidiary · France
- LeMaitre Co., Ltd Subsidiary · Thailand
- LeMaitre Ireland Ltd Subsidiary · Ireland
- LeMaitre Medical Technology (Shanghai) Co., Ltd Subsidiary · China
- LeMaitre Vascular GK Subsidiary · Japan
- LeMaitre Vascular S.r.l. Subsidiary · Italy
- LeMaitre Vascular Spain, S.L. Subsidiary · Spain
- LeMaitre Vascular Switzerland GmbH Subsidiary · Switzerland
- Vascutech Acquisition LLC Subsidiary · Delaware, United States
Built from subsidiaries listed in Exhibit 21 of annual reports filed with the SEC; major holders from Schedules 13D and 13G. Each entity in the chart links to its source.
What it owns
What LEMAITRE VASCULAR INC reports owning in its annual reports to the SEC: buildings, land and equipment, real estate and locations, investments, intangible assets and inventory, at the end of its latest fiscal year and a year before.
Property and equipment
| Item | Latest | A year before | Change |
|---|---|---|---|
| Computer equipment and software | $5.1M10 Dec 31, 2024 | $3.6M10 Dec 31, 2023 | +41.5% |
| Property and equipment, before depreciation | $55.4M6 Dec 31, 2025 | $49.0M6 Dec 31, 2024 | +13.0% |
| Accumulated depreciation | $28.4M6 Dec 31, 2025 | $24.2M6 Dec 31, 2024 | +17.3% |
| Property and equipment, net | $27.0M6 Dec 31, 2025 | $24.8M6 Dec 31, 2024 | +8.9% |
| Operating-lease assets (leased space) | $15.8M6 Dec 31, 2025 | $16.8M6 Dec 31, 2024 | −6.0% |
Investments
| Item | Latest | A year before | Change |
|---|---|---|---|
| Cash and cash equivalents | $28.2M6 Dec 31, 2025 | $25.6M6 Dec 31, 2024 | +10.3% |
| Marketable securities, current | $330.9M6 Dec 31, 2025 | $274.1M6 Dec 31, 2024 | +20.7% |
| Debt securities available for sale | $273.3M6 Dec 31, 2025 |
Intangibles and goodwill
| Item | Latest | A year before | Change |
|---|---|---|---|
| Goodwill | $65.9M6 Dec 31, 2025 | $65.9M6 Dec 31, 2024 | 0% |
| Intangible assets, net (excluding goodwill) | $33.1M6 Dec 31, 2025 | $35.8M6 Dec 31, 2024 | −7.6% |
| Finite-lived intangibles, gross | $74.9M6 Dec 31, 2025 | $72.0M6 Dec 31, 2024 | +4.0% |
| Accumulated amortization | $41.8M6 Dec 31, 2025 | $36.2M6 Dec 31, 2024 | +15.6% |
Inventory
| Item | Latest | A year before | Change |
|---|---|---|---|
| Raw materials | $20.9M6 Dec 31, 2025 | $19.1M6 Dec 31, 2024 | +9.3% |
| Work in process | $2.9M6 Dec 31, 2025 | $2.2M6 Dec 31, 2024 | +35.5% |
| Finished goods | $34.4M6 Dec 31, 2025 | $34.7M6 Dec 31, 2024 | −0.7% |
Properties, in its own words
As of December 31, 2025, our principal worldwide executive, distribution, and manufacturing operations are located at five leased facilities with square footage totaling 109,354 in Burlington, Massachusetts. Four of the five Burlington leases
expire in December 2034 and the fifth lease expires December 2030. We have no negotiated option to extend or renew the four leases beyond December 2034.
The rest of Item 2
In June 2025, the Company executed a new building lease agreement in Billerica, Massachusetts for U.S. distribution. The 34,400 square foot building lease commenced on January 1, 2026, with a primary term through December 31, 2032. The Company has the option to renew the primary term of the lease for one additional 24-month period.
Our European operations are headquartered at a 21,410 square foot leased facility located in Sulzbach, Germany, with a lease expiring in June 2031. Our Asia Pacific operations are headquartered at a 1,270 square foot leased facility located in Singapore, with a lease expiring in June 2026. We also lease additional manufacturing, processing, distribution, and sales offices in other North America, Europe, and Asia Pacific locations. Based on our current operating plans, we believe our current facilities are adequate for our needs.
Item 2 of the 10-K filed Feb 26, 2026.5
Leadership
Who has led LEMAITRE VASCULAR INC, and when. Pick a name to see everywhere that person has worked.
Chief executive
Chief financial officer
- Chief executive officerGeorge W. Lemaitre Oct 18, 2006 to now14
- ChairGeorge W. Lemaitre Oct 18, 2006 to now14
- PresidentDavid B. Roberts Mar 6, 2008 to now15
- PresidentGeorge W. Lemaitre Oct 18, 2006 to Mar 5, 200714
- PresidentPeter R. Gebauer Oct 18, 2006 to Sep 11, 201716
- Chief financial officerDorian Paul Leblanc Mar 21, 2025 to now17
- Chief financial officerJoseph P. Pellegrino Jr. Mar 6, 2008 to Mar 4, 202518
- Chief financial officerDavid B. Roberts Oct 18, 2006 to Jul 20, 200719
Board members and other officers (24)
- VP of Sales, The AmericasMichael T. Wijas Aug 28, 2015 to Jun 12, 201720
- VP, North American SalesRobert Linden V. Apr 29, 2008 to Jul 29, 201421
- V.P., Human Resources,DirectorCornelia W. Lemaitre Oct 18, 2006 to Jun 27, 201422
- V.P. Information TechnologyJonathan W. Ngau Oct 18, 2006 to Dec 22, 200623
- Executive V.P. FinanceJoseph P. Pellegrino Jr. Oct 18, 2006 to Jul 20, 200724
- V. P. North American SalesKevin D. Kelly Oct 18, 2006 to Mar 5, 200825
- Vice President, MarketingKimberly L. Cieslak Oct 18, 2006 to Mar 1, 200726
- V.P. Central European SalesMaik D. Helmers Oct 18, 2006 to Dec 22, 200627
- Director - R&DRyan H. Connelly Oct 18, 2006 to Nov 22, 200628
- Senior V. P., OperationsTrent G. Kamke Oct 18, 2006 to now29
- Board memberMartha Shadan Sep 23, 2022 to now30
- Board memberBridget A. Ross May 8, 2020 to now31
- Board memberJoseph P. Pellegrino Jr. Dec 7, 2016 to now32
- Board memberRussell D. Hays Jan 10, 2008 to Mar 10, 201433
- Board memberWilliam N. Thorndike Jr. Jun 20, 2008 to Jul 26, 201334
- Board memberCornelia W. Lemaitre Oct 18, 2006 to Aug 22, 201622
- Board memberDavid B. Roberts Oct 18, 2006 to now19
- Board memberDavid N. Gill Oct 18, 2006 to Jul 20, 200735
- Board memberDuane M. Desisto Oct 18, 2006 to Jul 20, 200736
- Board memberGeorge D. Lemaitre Oct 18, 2006 to Sep 5, 201237
- Board memberGuido J. Neels Oct 18, 2006 to Dec 22, 200638
- Board memberLawrence J. Jasinski Oct 18, 2006 to now39
- Board memberRyan H. Connelly Dec 22, 2006 to Dec 22, 200640
- General counselAaron M. Grossman Oct 18, 2006 to Sep 6, 201141
Subsidiaries and ownership
Subsidiaries (Exhibit 21)
- Bio Nova Holdings Pty Ltd Australia4
- Bio Nova International Pty Ltd Australia4
- LeMaitre Acquisition LLC Delaware4
- LeMaitre Acquisition Pty Ltd Australia4
- LeMaitre Cardial SAS France4
- LeMaitre Co., Ltd Thailand4
- LeMaitre Ireland Ltd Ireland4
- LeMaitre Medical Technology (Shanghai) Co., Ltd China4
- LeMaitre Pte Ltd Singapore4
- LeMaitre Vascular AS Norway4
- LeMaitre Vascular GK Japan4
- LeMaitre Vascular GmbH Germany4
- LeMaitre Vascular Pty Ltd Australia4
- LeMaitre Vascular S.r.l. Italy4
- LeMaitre Vascular SAS France4
- LeMaitre Vascular Spain, S.L. Spain4
- LeMaitre Vascular Switzerland GmbH Switzerland4
- LeMaitre Vascular ULC Canada4
- LeMaitre Vascular, Ltd United Kingdom4
- Vascutech Acquisition LLC Delaware4
The subsidiaries the company lists in Exhibit 21 of its annual report, as filed.
Timeline
- Oct 15, 20268-K Executive or director change42
- Aug 4, 20268-K Results of operations43
- Jun 5, 20268-K Shareholder vote44
- May 5, 20268-K Results of operations45
- Apr 14, 20268-K Executive or director change; Other events46
- Feb 25, 20268-K Results of operations47
- Nov 7, 20258-K Shareholder vote48
- Nov 6, 20258-K Results of operations49
- Aug 5, 20258-K Results of operations50
- Jun 3, 20258-K Shareholder vote51
- May 1, 20258-K Results of operations52
- Feb 27, 20258-K Results of operations53
- Oct 18, 2006New chief executive George W. Lemaitre becomes CEO14
Calendar
Coming up
- Nov 4, 2026 · After the closeReports results for the quarter ending Sep/2026 A year earlier it reported $0.62 a share, on Nov 6, 2025.54
When it reported results
- Aug 4, 2026Reported quarterly or annual results43
- May 5, 2026Reported quarterly or annual results45
- Feb 25, 2026Reported quarterly or annual results47
- Nov 6, 2025Reported quarterly or annual results49
- Aug 5, 2025Reported quarterly or annual results50
- May 1, 2025Reported quarterly or annual results52
- Feb 27, 2025Reported quarterly or annual results53
- Oct 31, 2024Reported quarterly or annual results55
Upcoming dates from Nasdaq's calendar; past results from the company's 8-K filings (Item 2.02). The full markets calendar
Filings
569 filings to the SEC since October 2021: 5 annual reports, 15 quarterly reports, 35 major events, 424 insider forms, 29 large holders, 61 other. The latest 20:
- Oct 15, 20268-K EDGAR
- Sep 8, 20264 EDGAR
- Sep 8, 20264 EDGAR
- Sep 8, 20264 EDGAR
- Sep 8, 20264 EDGAR
- Sep 8, 20264 EDGAR
- Sep 8, 20264 EDGAR
- Sep 8, 20264 EDGAR
- Sep 8, 20264 EDGAR
- Sep 8, 20264 EDGAR
- Sep 3, 20264 EDGAR
- Aug 5, 202610-Q EDGAR
- Aug 4, 20268-K EDGAR
- Jul 29, 2026144 EDGAR
- Jul 27, 2026SCHEDULE 13G EDGAR
- Jun 5, 20264 EDGAR
- Jun 5, 20264 EDGAR
- Jun 5, 20264 EDGAR
- Jun 5, 20264 EDGAR
- Jun 5, 20264 EDGAR
The 569 filings since October 2021 can be filtered by form type and year here when JavaScript is on.
Every filing from the last five years, summarized. The full record is on SEC EDGAR.
Insider trades
74 open-market trades by officers, directors and large owners since October 2021: 0 buys and 74 sales. Grants, option exercises and gifts are left out.
| Date | Who | Trade | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| May 8, 2026 | LeMaitre George WChairman and CEO | Sale | 27,881 | $108.69 | $3.0M | Form 4 |
| May 8, 2026 | Kamke Trent GSenior V. P., Operations | Sale | 2,928 | $107.00 | $313.3K | Form 4 |
| May 7, 2026 | LeMaitre George WChairman and CEO | Sale | 18,600 | $107.64 | $2.0M | Form 4 |
| May 7, 2026 | Ross Bridget ADirector | Sale | 5,044 | $111.10 | $560.4K | Form 4 |
| May 7, 2026 | Jasinski Lawrence JDirector | Sale | 3,943 | $110.00 | $433.7K | Form 4 |
| Mar 11, 2026 | Kamke Trent GSenior V. P., Operations | Sale | 2,625 | $108.50 | $284.8K | Form 4 |
| Mar 11, 2026 | Roberts David BPresident and Director | Sale | 3,312 | $107.68 | $356.6K | Form 4 |
| Mar 2, 2026 | LeMaitre George WChairman and CEO | Sale | 55,930 | $107.81 | $6.0M | Form 4 |
| Feb 27, 2026 | Kamke Trent GSenior V. P., Operations | Sale | 1,044 | $110.29 | $115.1K | Form 4 |
| Feb 27, 2026 | Roberts David BPresident and Director | Sale | 8,464 | $106.80 | $904.0K | Form 4 |
| Feb 26, 2026 | LeMaitre George WChairman and CEO | Sale | 150,000 | $106.76 | $16.0M | Form 4 |
| Aug 12, 2025 | Jasinski Lawrence JDirector | Sale | 976 | $92.78 | $90.6K | Form 4 |
| Aug 11, 2025 | Roberts David BPresident and Director | Sale | 10,815 | $92.38 | $999.1K | Form 4 |
| Aug 11, 2025 | Roush John ADirector | Sale | 6,561 | $92.55 | $607.2K | Form 4 |
| Aug 8, 2025 | Ross Bridget ADirector | Sale | 2,500 | $94.00 | $235.0K | Form 4 |
| Aug 8, 2025 | Roush John ADirector | Sale | 939 | $93.49 | $87.8K | Form 4 |
| Aug 6, 2025 | LeMaitre George WChairman and CEO | Sale | 100,000 | $93.51 | $9.4M | Form 4 |
| May 20, 2025 | LeMaitre George WChairman and CEO | Sale | 4,399 | $85.10 | $374.4K | Form 4 |
| May 19, 2025 | LeMaitre George WChairman and CEO | Sale | 76,868 | $85.79 | $6.6M | Form 4 |
| May 16, 2025 | LeMaitre George WChairman and CEO | Sale | 18,733 | $84.77 | $1.6M | Form 4 |
All 74 trades can be filtered by person here when JavaScript is on.
From Forms 4 filed with the SEC.
Major holders
Investors who own more than 5% of the shares must tell the SEC: a 13D if they may seek to influence the company, a 13G if they hold passively.
- FIRST TRUST PORTFOLIOS LPSCHEDULE 13G, 1 filing Jul 27, 202656
- George W. LemaitreSCHEDULE 13G/A, 6 filings Feb 11, 2022 to May 14, 202657
- VANGUARD GROUP INCSCHEDULE 13G/A, 4 filings Feb 10, 2022 to Mar 27, 202658
- Conestoga Capital Advisors, LLCSCHEDULE 13G/A, 5 filings Jan 10, 2022 to Jan 9, 202659
- BlackRockSCHEDULE 13G/A, 8 filings Jan 28, 2022 to Apr 29, 202560
- Copeland Capital Management, LLCSCHEDULE 13G, 5 filings Jan 26, 2022 to Jan 24, 202561
Executive pay
What the company paid its top executives, from the summary compensation table in its proxy statement. Total pay includes salary, bonus, stock and option awards and other pay, as the company valued them.
| Year | Executive | Age | Salary | Total pay |
|---|---|---|---|---|
| 2025 | George W. LeMaitre | 61 | $806.3K | $3.8M62 |
| 2025 | David B. Roberts | 61 | $452.7K | $1.3M62 |
| 2025 | Dorian P. LeBlanc | 51 | $445.5K | $1.1M62 |
| 2025 | Trent G. Kamke | 55 | $383.8K | $859.4K62 |
| 2025 | Joseph P. PellegrinoJr. | 61 | $88.8K | $335.9K62 |
| 2024 | Chairman and Chief | $622.3K | $3.2M62 | |
| 2024 | Former Chief Financial Officer | $419.9K | $1.3M62 | |
| 2024 | President | $406.8K | $1.1M62 | |
| 2024 | Senior VicePresident, | $316.6K | $859.4K62 | |
| 2023 | Executive Officer | $592.7K | $2.2M62 | |
| 2023 | President | $430.3K | $1.1M62 | |
| 2023 | Former Chief Financial Officer | $381.7K | $1.1M62 | |
| 2023 | Operations | $301.5K | $668.4K62 |
Held by these funds
The largest holders among investment managers' 13F reports for the quarter ending Jun 30, 2026, the top 25 of 100. Change is in shares since the quarter before.
| Fund | Shares | Value | Share of the fund | Change |
|---|---|---|---|---|
| BlackRock, Inc. | 3,272,973 | $314.1M | 0.0% | +128,822 |
| Conestoga Capital Advisors, LLC | 1,367,513 | $131.2M | 2.9% | −109,300 |
| First Trust Advisors LP | 1,093,502 | $104.9M | 0.1% | +95,431 |
| Congress Asset Management Co | 963,706 | $92.5M | 0.6% | +129,177 |
| Vanguard Capital Management LLC | 953,437 | $91.5M | 0.0% | +41,379 |
| State Street Corp | 901,416 | $86.5M | 0.0% | +45,632 |
| Copeland Capital Management, LLC | 839,463 | $80.6M | 1.7% | −31,229 |
| Geode Capital Management, LLC | 788,835 | $75.7M | 0.0% | +130,390 |
| Vanguard Portfolio Management LLC | 604,833 | $58.0M | 0.0% | +42,063 |
| Geneva Capital Management LLC | 589,064 | $56.5M | 1.3% | −164,928 |
| Dimensional Fund Advisors LP | 493,889 | $47.4M | 0.0% | +17,554 |
| Goldman Sachs Group Inc | 473,194 | $45.4M | 0.0% | +40,778 |
| Invesco Ltd. | 448,389 | $43.0M | 0.0% | +114,412 |
| Morgan Stanley | 351,083 | $33.7M | 0.0% | −56,688 |
| Northern Trust Corp | 333,325 | $32.0M | 0.0% | +20,770 |
| Two Sigma Investments, LP | 316,528 | $30.4M | 0.0% | +34,550 |
| Royal Bank Of Canada | 308,765 | $29.6M | 0.0% | +36,111 |
| Annex Advisory Services, LLC | 248,253 | $23.8M | 0.4% | −2,357 |
| UBS Group AG | 247,804 | $23.8M | 0.0% | +206,387 |
| Envestnet Asset Management Inc | 244,729 | $23.5M | 0.0% | −29,667 |
| Kennedy Capital Management LLC | 228,934 | $22.0M | 0.4% | −7,843 |
| Kayne Anderson Rudnick Investment Management LLC | 220,497 | $21.2M | 0.1% | −10,221 |
| Ranger Investment Management, L.P. | 219,307 | $21.0M | 1.3% | −19,053 |
| Sei Investments Co | 206,764 | $19.8M | 0.0% | +70,090 |
| Charles Schwab Investment Management Inc | 206,279 | $19.8M | 0.0% | +8,304 |
13F reports cover disclosed long positions in U.S. stocks only.
SEC filer profile
How LEMAITRE VASCULAR INC is registered with the Securities and Exchange Commission, from its EDGAR record and the cover page of its latest annual report.
- Name on EDGARLEMAITRE VASCULAR INC1
- CIK0001158895
- Employer ID (EIN)04-28254585
- Filer statusLarge accelerated filer not an emerging growth company; not a smaller reporting company; not a shell company5
- Incorporated inDelaware5
- Fiscal year endsDecember 311
- Industry code (SIC)3841 Surgical & Medical Instruments & Apparatus1
- SEC reviewing officeOffice of Industrial Applications and Services, Division of Corporation Finance1
- Business address63 Second Avenue, Burlington, MA 018031
- Phone781-221-22661
- Shares outstanding22,869,257 as of Aug 2, 202613
- Public float$1.7B as of Jun 30, 20255
- AuditorGRANT THORNTON LLP, Boston, Massachusetts PCAOB ID 248; it also attests to the company’s internal control over financial reporting5
- On EDGAR sinceJul 31, 20021
- Filings1,875 in all: 4 (1,296), 8-K (163), SC 13G/A (62), 10-Q (59), 4/A (48), 144 (44), 3 (31), SC 13G (26)1
All 36 form types
10-K (20), DEF 14A (20), SD (13), ARS (12), UPLOAD (9), SCHEDULE 13G/A (8), REGDEX (7), S-1/A (7), CORRESP (6), S-8 (6), 424B5 (4), 5 (4), 8-K/A (4), 10-K/A (3), 10-Q/A (3), DEFA14A (3), EFFECT (3), S-3 (2), S-8 POS (2), SCHEDULE 13G (2), 11-K (1), 3/A (1), 424B4 (1), 8-A12B (1), CERTNAS (1), CT ORDER (1), PRE 14A (1), S-1 (1)
- Latest filingsAnnual report (10-K) Feb 26, 2026
Quarterly report (10-Q) Aug 5, 2026
Proxy statement (DEF 14A) Apr 14, 2026
Latest 8-K (8-K) Oct 15, 2026
Securities registered for trading
| Class | Symbol | Exchange |
|---|---|---|
| Common stock, $0.01 par value per share | LMAT | The Nasdaq Global Market |
From the cover page of the 10-K filed Feb 26, 2026 (Section 12(b) of the Exchange Act).5
Risk factors and legal proceedings
The risks LEMAITRE VASCULAR INC names in Item 1A of its 10-K filed Feb 26, 2026: 34 risks under these headings, as written.5
- Risks Related to Our Business
- We may not be able to maintain our historic levels of profit growth.
- If we are unable to increase our selling prices to customers, or if we are required to make price concessions, our sales growth could be reduced and our operating results could suffer.
- We face competition from other medical device companies and alternative medical technologies, and we may not be able to compete effectively.
- If we are unable to source, acquire and integrate new businesses, product lines, or technologies, we may not achieve our growth objectives and our results of operations could suffer.
- Adverse global economic conditions and trade tensions could have a negative effect on our business, results of operations, and financial condition and liquidity.
- The risks inherent in operating internationally and the risks of selling and shipping our products and of purchasing our components and products internationally may adversely impact our net sales, results of operations, and financial condition.
- We may experience disruptions to our international business to the extent we transition our sales strategy in certain international jurisdictions from a distributor-based approach to a direct sales model.
- Our dependence on sole- and limited-source suppliers could hinder our ability to deliver our products and services to our customers and could harm our results of operations.
- Some of our devices are sold to a different call point, and we may not be successful in selling to that newer call point.
- Cybersecurity breaches, loss of data and other disruptions could compromise sensitive information related to our business or prevent us from accessing critical information and expose us to liability, which could adversely affect our business and our reputation.
- We depend on our information technology and telecommunications systems, and any failure of these systems could harm our business.
The other 23 risks
- We may experience challenges with the ongoing implementation of our new enterprise resource planning system.
- Our tissue processing and preservation services are subject to a variety of risks, including those related to the procurement of human tissue and regulatory requirements.
- Any disruption in our manufacturing facilities could harm our results of operations.
- The use or misuse of our products and the tissues we distribute may result in injuries that lead to product liability lawsuits or legal actions, which could be costly to our business.
- From time to time, we are involved in litigation where the outcome is uncertain and which could entail significant expense.
- If we are not able to navigate executive officer transitions and retain key personnel, our business may be harmed.
- Risks Related to the Regulatory Environment
- If we are not successful in obtaining additional and maintaining current clearances and approvals from U.S. governmental agencies for our medical devices, we might not be able to sell our products, and our future growth might be hampered.
- If we or some of our suppliers fail to comply with the FDA’s Quality Management System Regulation (QMSR) and other applicable requirements, our manufacturing or processing operations could be disrupted, and we may become subject to a variety of FDA enforcement actions.
- If we do not comply with international regulatory requirements to market our products or if we need to modify our operations or products as a result of such requirements, our business may be harmed.
- Oversight of the medical device industry might affect the manner in which we may sell medical devices and compete in the marketplace.
- Even after our products have received marketing approval or clearance, our products and the tissue we process may be subject to recall. Licenses, registrations, approvals, and clearances could be withdrawn or suspended due to failure to comply with regulatory standards or the occurrence of unforeseen problems following initial approval.
- Certain of our products contain materials derived from animal sources and may become subject to additional regulation.
- We may incur additional costs or encounter supply challenges if chemicals or substances used in the manufacture, packaging, or sterilization of our products are restricted or banned as a result of environmental concerns.
- Our human tissue cryopreservation services are subject to a wide variety of federal, state, and international regulations, and our failure to comply would impair our ability to operate in that space and negatively affect our operating results.
- Risks Related to Our Debt
- Servicing our 2.50% convertible senior notes requires a significant amount of cash, and we may not have sufficient cash flow to pay our debt.
- We may not have the ability to raise the funds necessary to repurchase the Convertible Notes as required upon a fundamental change, and our future debt may contain limitations on our ability to repurchase the Convertible Notes.
- The conditional conversion feature of the Convertible Notes, if triggered, may adversely affect our liquidity.
- Transactions relating to the Convertible Notes may affect the value of our common stock.
- Risks Related to Intellectual Property
- If we fail to adequately protect our intellectual property rights, or prevent use of our intellectual property by third parties, we could lose a significant competitive advantage and our business may suffer.
- If third parties claim that we infringe upon their intellectual property rights, we may incur liabilities and costs, and we may have to redesign or discontinue selling the affected product.
- Risks Related to Our Common Stock
- Our stock price may be volatile, and an investment in our common stock could suffer a decline in value.
- Our Chief Executive Officer and Chairman of the Board has significant voting power and may take actions that may not align with the interests of our other stockholders.
- We have not established a minimum dividend payment level for our common stockholders and there are no assurances of our ability to pay dividends to common stockholders in the future.
Legal proceedings
In the ordinary course of business, we are from time to time involved in lawsuits, claims, investigations, proceedings, and threats of litigation consisting of intellectual property, contractual, commercial, employment, and other matters. While the outcome of these proceedings and claims cannot be predicted with certainty, there are no matters, as of December 31, 2025, that, in the opinion of management, would be reasonably expected to have a material adverse effect on our financial position, results of operations or cash flows.
The opening of Item 3, Legal Proceedings.5
Sources
The numbers on this page point here. Each one links to the record it came from.
- 1
- 2Yahoo FinanceLMAT quote
- 3
- 4
- 5
- 6
- 7
- 8
- 9
- 10
- 11
- 12
- 13
- 14
- 15SEC EDGARDavid B. Roberts, President
- 16SEC EDGARPeter R. Gebauer, President
- 17
- 18
- 19
- 20
- 21
- 22
- 23
- 24
- 25
- 26
- 27
- 28SEC EDGARRyan H. Connelly, Director - R&D
- 29
- 30SEC EDGARMartha Shadan, Board member
- 31SEC EDGARBridget A. Ross, Board member
- 32
- 33SEC EDGARRussell D. Hays, Board member
- 34
- 35SEC EDGARDavid N. Gill, Board member
- 36SEC EDGARDuane M. Desisto, Board member
- 37SEC EDGARGeorge D. Lemaitre, Board member
- 38SEC EDGARGuido J. Neels, Board member
- 39SEC EDGARLawrence J. Jasinski, Board member
- 40SEC EDGARRyan H. Connelly, Board member
- 41SEC EDGARAaron M. Grossman, General counsel
- 42SEC EDGARExecutive or director change
- 43SEC EDGARResults of operations
- 44SEC EDGARShareholder vote
- 45SEC EDGARResults of operations
- 46
- 47SEC EDGARResults of operations
- 48SEC EDGARShareholder vote
- 49SEC EDGARResults of operations
- 50SEC EDGARResults of operations
- 51SEC EDGARShareholder vote
- 52SEC EDGARResults of operations
- 53SEC EDGARResults of operations
- 54NasdaqNasdaq calendar
- 55
- 56
- 57
- 58
- 59
- 60
- 61
- 62